Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
This two-part study will include a dose escalation part to determine the recommended dose for expansion of DS8201a and pembrolizumab and a dose expansion part to evaluate efficacy, safety, and tolerability of the combination.
Full description
This phase 1b, open-label, 2-part, multicenter, non-randomized, multiple-dose study will evaluate DS-8201a in combination with pembrolizumab in participants with advanced/metastatic breast cancer or non-small cell lung cancer (NSCLC).
In the dose escalation part of the study, escalating doses of DS-8201a in combination with pembrolizumab will be assessed. DS-8201a and pembrolizumab 200 mg will be administered on Day 1 of every 21-day cycle. The initial dose administered for DS8201a will be 3.2 mg/kg Q3W. Escalation to the next dose (5.4 mg/kg Q3W) will be based on acceptable safety signals based on the earlier dose cohort.
Upon completion of dose escalation with the recommended dose of escalation (RDE) established, the dose expansion part of the study will begin. The dose expansion part will include 4 cohorts: Human epidermal growth factor receptor 2 (HER2+) breast cancer participants with prior ado-trastuzumab emtansine (T-DM1), HER2 low breast cancer participants with prior failed standard treatments, HER2-expressing NSCLC participants who have not received any prior treatment with anti-PD-1, anti-PD-L1, or HER2 agents, and HER2-mutant NSCLC participants who have not received any prior treatment with anti-PD-1, anti-PD-L1, or HER2 agents.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Inclusion Criteria Specific to Part 1
Inclusion Criteria Specific to Part 2
Inclusion Criteria for Cohort 1
Inclusion Criteria for Cohort 2
Inclusion Criteria for Cohort 3
Inclusion Criteria for Cohort 4
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
115 participants in 5 patient groups
Loading...
Central trial contact
AZ Breast Cancer Study Navigators; Daiichi Sankyo Contact for Clinical Trial Information
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal